CRISPR Therapeutics AG
CRSP
$38.27
-$0.84-2.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -89.95% | 19.31% | 18.89% | 171.01% | 30,885.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -89.95% | 19.31% | 18.89% | 171.01% | 30,885.48% |
| Cost of Revenue | -16.75% | -9.54% | -12.54% | -11.77% | -9.50% |
| Gross Profit | -168.89% | 23.85% | 26.45% | 51.19% | 74.35% |
| SG&A Expenses | -4.18% | -11.77% | -19.38% | -25.88% | -25.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.14% | -9.84% | -13.49% | -13.84% | -11.95% |
| Operating Income | -109.66% | 21.54% | 25.12% | 46.83% | 66.94% |
| Income Before Tax | -140.62% | 34.38% | 37.90% | 59.20% | 76.83% |
| Income Tax Expenses | 24.20% | 145.74% | 134.02% | 187.72% | 988.62% |
| Earnings from Continuing Operations | -138.43% | 32.23% | 36.09% | 58.56% | 76.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -138.43% | 32.23% | 36.09% | 58.56% | 76.37% |
| EBIT | -109.66% | 21.54% | 25.12% | 46.83% | 66.94% |
| EBITDA | -120.67% | 22.29% | 25.97% | 48.19% | 68.77% |
| EPS Basic | -123.71% | 37.49% | 39.60% | 59.84% | 76.72% |
| Normalized Basic EPS | -125.77% | 39.50% | 41.31% | 60.46% | 77.17% |
| EPS Diluted | -121.12% | 36.73% | 39.02% | 59.41% | 76.42% |
| Normalized Diluted EPS | -123.12% | 39.00% | 40.89% | 60.12% | 76.90% |
| Average Basic Shares Outstanding | 6.48% | 5.11% | 3.72% | 2.38% | 1.90% |
| Average Diluted Shares Outstanding | 5.94% | 5.63% | 4.24% | 2.90% | 2.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |